Cargando…

Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study

BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined the impact of different PrEP strategies on averting new infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Brooke E., Boucher, Charles A. B., van Dijk, Janneke H., Thuma, Phil E., Nouwen, Jan L., Baltussen, Rob, van de Wijgert, Janneke, Sloot, Peter M. A., van de Vijver, David A. M. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601101/
https://www.ncbi.nlm.nih.gov/pubmed/23527217
http://dx.doi.org/10.1371/journal.pone.0059549
_version_ 1782475717898928128
author Nichols, Brooke E.
Boucher, Charles A. B.
van Dijk, Janneke H.
Thuma, Phil E.
Nouwen, Jan L.
Baltussen, Rob
van de Wijgert, Janneke
Sloot, Peter M. A.
van de Vijver, David A. M. C.
author_facet Nichols, Brooke E.
Boucher, Charles A. B.
van Dijk, Janneke H.
Thuma, Phil E.
Nouwen, Jan L.
Baltussen, Rob
van de Wijgert, Janneke
Sloot, Peter M. A.
van de Vijver, David A. M. C.
author_sort Nichols, Brooke E.
collection PubMed
description BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined the impact of different PrEP strategies on averting new infections, prevalence, drug resistance and cost-effectiveness in Macha, a rural setting in Zambia. METHODS: A deterministic mathematical model of HIV transmission was constructed using data from the Macha epidemic (antenatal prevalence 7.7%). Antiretroviral therapy is started at CD4<350 cells/mm(3). We compared the number of infections averted, cost-effectiveness, and potential emergence of drug resistance of two ends of the prioritization spectrum: prioritizing PrEP to half of the most sexually active individuals (5–15% of the total population), versus randomly putting 40–60% of the total population on PrEP. RESULTS: Prioritizing PrEP to individuals with the highest sexual activity resulted in more infections averted than a non-prioritized strategy over ten years (31% and 23% reduction in new infections respectively), and also a lower HIV prevalence after ten years (5.7%, 6.4% respectively). The strategy was very cost-effective at $323 per quality adjusted life year gained and appeared to be both less costly and more effective than the non-prioritized strategy. The prevalence of drug resistance due to PrEP was as high as 11.6% when all assumed breakthrough infections resulted in resistance, and as low as 1.3% when 10% of breakthrough infections resulted in resistance in both our prioritized and non-prioritized scenarios. CONCLUSIONS: Even in settings with low test rates and treatment retention, the use of PrEP can still be a useful strategy in averting infections. Our model has shown that PrEP is a cost-effective strategy for reducing HIV incidence, even when adherence is suboptimal and prioritization is imperfect.
format Online
Article
Text
id pubmed-3601101
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36011012013-03-22 Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study Nichols, Brooke E. Boucher, Charles A. B. van Dijk, Janneke H. Thuma, Phil E. Nouwen, Jan L. Baltussen, Rob van de Wijgert, Janneke Sloot, Peter M. A. van de Vijver, David A. M. C. PLoS One Research Article BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined the impact of different PrEP strategies on averting new infections, prevalence, drug resistance and cost-effectiveness in Macha, a rural setting in Zambia. METHODS: A deterministic mathematical model of HIV transmission was constructed using data from the Macha epidemic (antenatal prevalence 7.7%). Antiretroviral therapy is started at CD4<350 cells/mm(3). We compared the number of infections averted, cost-effectiveness, and potential emergence of drug resistance of two ends of the prioritization spectrum: prioritizing PrEP to half of the most sexually active individuals (5–15% of the total population), versus randomly putting 40–60% of the total population on PrEP. RESULTS: Prioritizing PrEP to individuals with the highest sexual activity resulted in more infections averted than a non-prioritized strategy over ten years (31% and 23% reduction in new infections respectively), and also a lower HIV prevalence after ten years (5.7%, 6.4% respectively). The strategy was very cost-effective at $323 per quality adjusted life year gained and appeared to be both less costly and more effective than the non-prioritized strategy. The prevalence of drug resistance due to PrEP was as high as 11.6% when all assumed breakthrough infections resulted in resistance, and as low as 1.3% when 10% of breakthrough infections resulted in resistance in both our prioritized and non-prioritized scenarios. CONCLUSIONS: Even in settings with low test rates and treatment retention, the use of PrEP can still be a useful strategy in averting infections. Our model has shown that PrEP is a cost-effective strategy for reducing HIV incidence, even when adherence is suboptimal and prioritization is imperfect. Public Library of Science 2013-03-18 /pmc/articles/PMC3601101/ /pubmed/23527217 http://dx.doi.org/10.1371/journal.pone.0059549 Text en © 2013 Nichols et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Nichols, Brooke E.
Boucher, Charles A. B.
van Dijk, Janneke H.
Thuma, Phil E.
Nouwen, Jan L.
Baltussen, Rob
van de Wijgert, Janneke
Sloot, Peter M. A.
van de Vijver, David A. M. C.
Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
title Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
title_full Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
title_fullStr Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
title_full_unstemmed Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
title_short Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
title_sort cost-effectiveness of pre-exposure prophylaxis (prep) in preventing hiv-1 infections in rural zambia: a modeling study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601101/
https://www.ncbi.nlm.nih.gov/pubmed/23527217
http://dx.doi.org/10.1371/journal.pone.0059549
work_keys_str_mv AT nicholsbrookee costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT bouchercharlesab costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT vandijkjannekeh costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT thumaphile costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT nouwenjanl costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT baltussenrob costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT vandewijgertjanneke costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT slootpeterma costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy
AT vandevijverdavidamc costeffectivenessofpreexposureprophylaxisprepinpreventinghiv1infectionsinruralzambiaamodelingstudy